News
May 24, 2024
Vinnova awards MedVasc a grant for a better understanding of reimbursement in the US
MedVasc has been awarded a grant of SEK 135,000 from Vinnova (Swedish Innovation Agency) to enhance the company’s understanding of the reimbursement landscape in the US. This support was secured through the Medtech4Health call 2024, aiming at strengthening small medtech companies through external competence. By the end of the…
May 3, 2024
SolutioTM featured on center stage at 2024 International Venous Conference
MedVasc anesthesia catheter SolutioTM gained attention during 2024 International Venous Conference as renowned KOL Dr. Lowell Kabnick gave a talk about next-generation venous devices: …
May 3, 2024
SolutioTM featured in Venous News and Vascular specialist
We are happy to announce that MedVasc anesthesia catheter SolutioTM has gained attention from important international newspapers within the industry. Please read and watch a short video of Founder Dr. Michael Åkesson in Venous News talking about the results from our first-in-man study: Vascular Specialist also wrote about the results from our…
May 3, 2024
Successful closing of SEK 5 million bridge-round
MedVasc has closed an investment round of 5 M SEK from existing investors. The raised capital will be used to initiate manufacturing and final validation of FDA 510k pathway for the company’s anesthesia catheter SolutioTM. SolutioTM improves the golden standard methods for treatment of varicose veins and is expected…
May 3, 2024
Medvasc’s patent portfolio granted in all prioritized jurisdictions
During 2023 MedVasc patent was granted in China, India, Canada, and Brazil. MedVasc’s patent portfolio is strengthened by the progression relating to the company’s medical device, the anesthesia catheter SolutioTM. SolutioTM minimizes the pain when performing the gold standard treatment methods for treating varicose veins and is expected to…
For press inquiries, please send an email
Subscribe to our newsletter
For more information on how we process your personal data please see our Privacy Notice
